These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9119932)

  • 61. Allogeneic bone marrow transplantation for multiple myeloma.
    Ballester OF
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):67-71. PubMed ID: 8211218
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel approaches in myeloma therapy.
    Munshi NC; Barlogie B; Desikan KR; Wilson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):28-34. PubMed ID: 10528892
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Encephalopathy complicating high-dose melphalan.
    Schuh A; Dandridge J; Haydon P; Littlewood TJ
    Bone Marrow Transplant; 1999 Nov; 24(10):1141-3. PubMed ID: 10578165
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
    Bahlis NJ; Lazarus HM
    Bone Marrow Transplant; 2006 Jul; 38(1):7-15. PubMed ID: 16715110
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for multiple myeloma].
    Kosugi H
    Rinsho Ketsueki; 2015 Mar; 56(3):279-88. PubMed ID: 25876781
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High-dose therapy in multiple myeloma.
    Samson D
    Curr Opin Hematol; 1996 Nov; 3(6):446-52. PubMed ID: 9372116
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chronic eyelid swelling as an initial manifestation of myeloma-associated amyloidosis.
    Chee E; Kim YD; Lee JH; Woo KI
    Ophthalmic Plast Reconstr Surg; 2013; 29(1):e12-4. PubMed ID: 22955341
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
    Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
    Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Myeloablative therapy for primary resistant multiple myeloma.
    Alexanian R; Dimopoulos MA; Delasalle KB; Hester J; Champlin R
    Stem Cells; 1995 Aug; 13 Suppl 2():118-21. PubMed ID: 8520499
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.
    Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Lal R; Singhal S; Mehta J; Horton C; Treleaven J
    Bone Marrow Transplant; 2001 Jul; 28(1):29-37. PubMed ID: 11498741
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea.
    Kang J; Hong JY; Yoon DH; Kim S; Lee KM; Park JS; Park CJ; Min WK; Seo EJ; Jang S; Suh C
    Acta Haematol; 2018; 139(3):185-192. PubMed ID: 29635247
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Allogeneic haemopoietic stem cell transplantation for multiple myeloma or plasma cell leukaemia using fractionated total body radiation and high-dose melphalan conditioning.
    Russell N; Bessell E; Stainer C; Haynes A; Das-Gupta E; Byrne J
    Acta Oncol; 2000; 39(7):837-41. PubMed ID: 11145442
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intensive therapy in AL amyloidosis and light-chain deposition disease.
    Mariette X; Clauvel JP; Brouet JC
    Ann Intern Med; 1995 Oct; 123(7):553. PubMed ID: 7661505
    [No Abstract]   [Full Text] [Related]  

  • 75. Donor cell leukemia developing after hematopoietic stem cell transplantation for multiple myeloma.
    Havelange V; Antoine-Poirel H; Saussoy P; Van Den Neste E; Ferrant A
    Acta Clin Belg; 2006; 61(2):82-6. PubMed ID: 16792340
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of bone marrow transplantation in the disease pathway of myeloma.
    Harousseau JL; Moreau P
    J Natl Compr Canc Netw; 2007 Feb; 5(2):163-9. PubMed ID: 17335685
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
    Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
    Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multiple myeloma presenting as plasmacytoma of the base of the skull.
    Alegre A; Tomás JF; Pinilla I; Gil-Fernández JJ; Fernández-Rañada JM
    Am J Hematol; 1996 May; 52(1):60-1. PubMed ID: 8638614
    [No Abstract]   [Full Text] [Related]  

  • 79. [Multiple myeloma. Diagnosis and therapy].
    Goldschmidt H; Cremer FW; Möhler TM; Ho AD
    Internist (Berl); 2003 May; 44(5):599-600, 603-16; quiz 617-8. PubMed ID: 12966788
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recent advances in the treatment of multiple myeloma.
    Henick K; Vescio RA; Berenson JR
    Curr Opin Hematol; 1998 Jul; 5(4):254-8. PubMed ID: 9747631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.